Mallinckrodt completes $425 million deal

Mallinckrodt has closed on its acquisition of specialty pharmaceutical firm InfaCare Pharmaceutical Corp. The deal, which was announced in August, could be worth as much as $425 million. Trevose, Pennsylvania-based InfaCare is focused on developing treatments for neonatal and pediatric patients. The company currently is developing a therapy, known as stannsoporfin, to treat newborns at risk of develo ping jaundice. "The addition of stannsoporfin further expands and diversifies Mallinckrodt's pediatric…
Source: bizjournals.com Health Care:Biotechnology headlines - Category: Biotechnology Authors: Source Type: news